How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Fertility Preservation Service Market
- By Service Type: Oocyte Cryopreservation, Sperm Cryopreservation, Embryo Cryopreservation, Ovarian Tissue Cryopreservation, Testicular Tissue Cryopreservation
- By End User: Oncology Patients, Non-Oncological Medical Conditions, Elective Fertility Preservation, Transgender Individuals, Delayed Childbearing
- By Technology: Vitrification, Slow Freezing, In Vitro Maturation (IVM), Cryoprotectant Agents
- By Procedure Setting: Hospital-Based Fertility Clinics, Standalone Fertility Centers, Specialized Cryobanks
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Oocyte Cryopreservation leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.165 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.173 →
Full report · locked preview
Everything inside the Fertility Preservation Service Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
End User 5
Technology 4
Procedure Setting 3
Companies profiled
CooperSurgical Inc.
Ferring Pharmaceuticals
Cryo-Save AG
OvaScience Inc.
ReproTech Ltd.
Vitrolife AB
Genea Biomedx Pty Ltd.
Origio A/S
Irvine Scientific Sales Company Inc.
Cook Medical
Mediware Information Systems
SAGE Fertility & Reproductive Medicine
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →CooperSurgical Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Ferring Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Cryo-Save AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →OvaScience Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ReproTech Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Vitrolife AB
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Genea Biomedx Pty Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Origio A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Irvine Scientific Sales Company Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Cook Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Mediware Information Systems
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →SAGE Fertility & Reproductive Medicine
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Fairfax Cryobank
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →European Sperm Bank
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →CryoCell International
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,603M by 2033 · 11.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Oocyte Cryopreservation55.9
- Sperm Cryopreservation8.8
- Embryo Cryopreservation13.7
- Ovarian Tissue Cryopreservation8.4
- Testicular Tissue Cryopreservation13.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,060M → $2,748M · 12.6%
Europe$739.0M → $1,746M · 11.3%
Asia Pacific$674.8M → $1,687M · 12.1%
Latin America$417.7M → $886.9M · 9.9%
Middle East and Africa$321.3M → $841.6M · 12.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.322026
11.322027
11.352028
11.352029
11.372030
11.382031
11.392032
11.402033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- CooperSurgical Inc.13.1
- Ferring Pharmaceuticals20.6
- Cryo-Save AG10.6
- OvaScience Inc.12.5
- ReproTech Ltd.11.4
- Vitrolife AB3.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type16.0%
End User31.6%
Technology15.0%
Procedure Setting37.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe22.1
- Asia Pacific21.3
- Latin America11.2
- Middle East and Africa10.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| CooperSurgical Inc. | 94 | 83 | 82 | 98 | 87 | 78 | 87 |
| Ferring Pharmaceuticals | 91 | 71 | 81 | 92 | 91 | 71 | 83 |
| Cryo-Save AG | 80 | 84 | 73 | 79 | 67 | 79 | 77 |
| OvaScience Inc. | 62 | 65 | 81 | 61 | 74 | 66 | 68 |
| ReproTech Ltd. | 69 | 67 | 74 | 69 | 71 | 60 | 68 |
| Vitrolife AB | 59 | 47 | 60 | 46 | 49 | 63 | 54 |
| Genea Biomedx Pty Ltd. | 53 | 59 | 65 | 64 | 64 | 50 | 59 |
| Origio A/S | 42 | 48 | 40 | 50 | 40 | 43 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- CooperSurgical Inc.
- Ferring Pharmaceuticals
- Cryo-Save AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| CooperSurgical Inc. | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Ferring Pharmaceuticals | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Cryo-Save AG | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| OvaScience Inc. | − | ◐ | ✓ | ◐ | ✓ | ◐ |
| ReproTech Ltd. | ◐ | − | ◐ | ◐ | ◐ | − |
| Vitrolife AB | ◐ | − | ◐ | − | − | ◐ |
| Genea Biomedx Pty Ltd. | − | ◐ | ◐ | ◐ | − | ◐ |
| Origio A/S | − | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1CooperSurgical Inc.87
2Ferring Pharmaceuticals83
3Cryo-Save AG77
4OvaScience Inc.68
5ReproTech Ltd.68
6Genea Biomedx Pty Ltd.59
7Vitrolife AB54
8Origio A/S44
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
CooperSurgical Inc.Ferring Pharmaceuticals
Challenger3
Strong scale, closing on the leaders.
Cryo-Save AGOvaScience Inc.ReproTech Ltd.
Contender1
Focused players with pockets of strength.
Genea Biomedx Pty Ltd.
Niche2
Specialists in a single segment or region.
Vitrolife ABOrigio A/S
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Fertility Preservation Service Market — a $196M beachhead inside a $3.05B market.
Beachhead (SOM)$196Mobtainable near-term
Serviceable (SAM)$1.07Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Oocyte Cryopreservation
Best fit — highest urgency & budget in Service Type.
Economic buyer78 fit
Sperm Cryopreservation
Strong fit — clear ROI and a fast path to value.
End user69 fit
Embryo Cryopreservation
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel26%
Digital / self-serve21%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Fertility Preservation Service Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified21%
Evaluation15%
Closed-won7%
$19.6KCAC
$93KLTV
4.8:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Fertility Preservation Service Market is a resilient opportunity — $3.92B by 2033, compounding at 4.6%.
TAM · 2025$2.74Btoday
TAM · 2033$3.92Bforecast
CAGR4.6%2027–2033
Cumulative$29.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.92BTotal addressable market
SAM$1.63BServiceable available market
SOM$319MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.6% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.92BLarge & growingTAM by 2033 at 4.6% CAGR
$1.63BServiceable nowreachable with today’s model
$319MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.06BBear3.0% CAGR
$3.92BBase4.6% CAGR
$5.02BBull6.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Fertility Preservation Service Market — a $4.44B market by 2033. Plan: grow share from 9.5% to 15.0%.
Market size · 2033$4.44Btotal addressable
Market CAGR9.6%2027–2033
Target share15.0%from 9.5% today
Revenue ambition$666Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.5% | 15.0% | On track |
| Revenue | $451M | $666M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 31.2% | 38.3% | Behind |
| Customer retention | 87.4% | 96.2% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $67M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Fertility Preservation Service Market conversation — a $2.60B market you can size, segment and defend in minutes.
Market size · 2033$2.60Btotal opportunity
Growth9.3%CAGR to 2033
Addressable buyers1,370+accounts in scope
Typical ROI7.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.6×return on cost, year one
< 4 mopayback period
$62K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
CooperSurgical Inc.Ferring PharmaceuticalsCryo-Save AGOvaScience Inc.ReproTech Ltd.Vitrolife ABGenea Biomedx Pty Ltd.Origio A/S+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Fertility Preservation Service Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Fertility Preservation Service Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Fertility-friendly Lubricant Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportFertility ELISA Test Kit Market
Market size, share, segmentation and regional forecast.
$678M market · 2025 base year
View reportOrganic Curcumin Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportCannabis Market
Cannabis Market is valued at USD 411 Billion in 2025 and is expected to reach USD 962 Billion b…
$411.0B market · 2025 base year
View reportFerrous Succinate Tablets Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportFerrous Succinate API Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportFerrous Picolinate Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportFerrous Bisglycinate Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportFerrous Ascorbate Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportFerrous Ascorbate API Market
Market size, share, segmentation and regional forecast.
$317M market · 2025 base year
View reportFerritin Testing Service Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportFerritin FIA Test Kit Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.